Naturally circulating dendritic cells to vaccinate cancer patients
Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step...
Main Authors: | Bol, Kalijn F., Tel, Jurjen, de Vries, I. Jolanda M., Figdor, Carl G. |
---|---|
Format: | Online |
Language: | English |
Published: |
Landes Bioscience
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661171/ |
Similar Items
-
Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
by: Bol, Kalijn, et al.
Published: (2015) -
Harnessing human plasmacytoid dendritic cells as professional APCs
by: Tel, Jurjen, et al.
Published: (2012) -
Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination
by: Wimmers, Florian, et al.
Published: (2015) -
Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
by: Wimmers, Florian, et al.
Published: (2014) -
Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
by: Schreibelt, Gerty, et al.
Published: (2013)